Search the Newsreel

Heron Incurs Wider Loss In Q2; Withdraws 2026 Guidance Amid Patent Litigation Over CINVANTI

(RTTNews) - Heron Therapeutics Inc. (HRTX), a commercial-stage biotechnology company, on Monday released second quarter financial results noting a higher loss due to increased sales expenses and decreased sales of oncology drugs. Heron markets various therapeutics, including ZYNRELEF, an extended-release local anesthetic, APONVIE for …

Laba DFI Retail Nusantara (HERO) Turun 16,6% di Semester I-2026

H.C. Wainwright Downgrades Heron Therapeutics(HRTX.US) to Hold Rating

H.C. Wainwright has downgraded Heron Therapeutics (HRTX.US) from a Buy to a Hold rating. This change in rating reflects a revised outlook from the firm regarding the pharmaceutical company.

Heron Therapeutics Inc (HRTX) (Q2 2026) Earnings Call Highlights: Revenue Growth Amid Strategic ...

Heron Therapeutics reported Q2 2026 net revenue of $37.7 million, an increase from both the previous quarter and the prior year, driven by strong growth in ZYNRELEF and APONVIE sales, and improved Adjusted EBITDA. However, net revenue fell short of expectations due to slower …

Heron Therapeutics Q2 2026 Loss Widens 50.0% Beyond Estimates

Heron Therapeutics (NASDAQ: HRTX) reported a Q2 2026 diluted loss of $0.03 per share, exceeding analyst estimates by 50.0%, and revenue of $37.7 million, which fell 10.7% short of expectations. The company experienced a 1.6% stock drop as its largest segment, Oncology, saw a …

Heron outlines covenants through 2027 and pro forma cash of $24.3M after September debt payment

Earnings Call Insights: Heron Therapeutics (HRTX) Q2 2026 MANAGEMENT VIEW * “Net revenue for the quarter was $37.7 million… it is below what we expected of ourselves,” said (CEO & Director Craig Collard), adding that “CINVANTI sales were up compared to Q1 in a …

Heron Therapeutics Withdraws 2026 Guidance as CINVANTI Patent Risk and Strategic Review Cloud Outlook

Heron Therapeutics has withdrawn its full-year 2026 financial guidance due to uncertainty surrounding potential generic competition for its key product, CINVANTI, following a recent court decision. The company's second-quarter revenue was below expectations, with strong growth in Acute Care revenue (ZYNRELEF and APONVIE) not …

Heron Therapeutics earnings missed by $0.02, revenue fell short of estimates

Heron Therapeutics (NASDAQ: HRTX) reported a second-quarter EPS of $-0.030, missing analyst estimates by $0.02, and revenue of $37.67M, falling short of the consensus estimate of $42.13M. The company's stock has seen significant declines over the past 3 and 12 months. InvestingPro rates Heron …

Earnings call transcript: Heron Therapeutics misses Q2 2026 revenue forecast

Heron Therapeutics reported Q2 2026 revenue of $37.7 million, missing the forecast of $42.13 million, leading to an 18.74% drop in stock price. The company withdrew its full-year guidance due to uncertainty surrounding its CINVANTI franchise patent ruling, changes in spending, and a review …

Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates

Heron Therapeutics (HRTX) reported a Q2 loss of $0.03 per share, missing the Zacks Consensus Estimate of a $0.02 loss and representing an earnings surprise of -50.00%. The company also failed to meet revenue estimates, posting $37.67 million against an expectation of $42.39 million. …

Heron Therapeutics reports Q2 2026 revenue $37.7M, withdraws 2026 guidance after patent ruling

Heron Therapeutics announced Q2 2026 net revenue of $37.7 million and a net loss of $5.5 million, ending the quarter with $42.7 million in cash. The company withdrew its full-year 2026 guidance following an unfavorable Delaware court decision impacting CINVANTI patents and is evaluating …

Heron Therapeutics Announces Second Quarter 2026 Financial Results

Heron Therapeutics announced its Q2 2026 financial results, with net revenue of $37.7 million, a 9% increase from Q1 2026. The company saw significant year-over-year growth in ZYNRELEF® (35%) and APONVIE® (74%) net revenue, but withdrew its full-year 2026 financial guidance due to uncertainty …

Heron Therapeutics Q2 Revenue Rises To $37.7 Million

Heron Therapeutics reported a 1.3% year-over-year increase in Q2 2026 net revenue, reaching $37.7 million, with acute care and specific product revenues showing significant growth, although oncology revenue declined. The company posted a net loss of $5.5 million and withdrew its full-year 2026 guidance. …

Heron Therapeutics: Q2 Earnings Snapshot

Heron Therapeutics Inc. (HRTX) reported a second-quarter loss of $5.5 million, translating to 3 cents per share. The pharmaceutical company, based in Cary, North Carolina, also announced revenues of $37.7 million for the period. This financial summary was generated using data from Zacks Investment …

Uber Technologies Q2 Earnings Call Highlights

Key Points Interested in Uber Technologies, Inc.? Here are five stocks we like better. Uber delivered strong Q2 growth: Gross bookings increased 22% year over year to more than $58 billion, while non-GAAP EPS rose 35% and trailing 12-month free cash flow exceeded $10 …

Wall Street Zen Upgrades Heron Therapeutics (NASDAQ:HRTX) to Sell

Wall Street Zen has upgraded Heron Therapeutics (NASDAQ: HRTX) to a "sell" rating, contrasting with the broader analyst consensus of "hold." The biotechnology company recently missed quarterly earnings and revenue expectations, reporting a loss of $0.04 per share against a $0.03 consensus loss and …

MoneyHero Ltd (MNY) awards 42,556 RSUs to board director

MoneyHero Ltd director Wallace Nung Pai was granted 42,556 restricted share units (RSUs) on July 31, 2026. These RSUs, which represent a contingent right to receive one Class A ordinary share each, will fully vest on August 17, 2026, provided his continued service. This …

MoneyHero Ltd (MNY) awards 12,051 RSUs to Chief Commercial Officer

MoneyHero Ltd's Chief Commercial Officer, Shravan Thakur, was granted 12,051 restricted share units (RSUs), with each RSU representing a Class A ordinary share. These RSUs vest in installments, beginning June 26, 2026, and concluding February 15, 2028, contingent on his continued service. Following this …

MoneyHero Ltd (MNY) director granted 42,556 RSUs vesting in 2026

MoneyHero Ltd. (MNY) director Daniel Hua-chang Wang was granted 42,556 restricted share units (RSUs), which are set to vest 100% on August 17, 2026, provided he remains with the company. The grant price for these RSUs was $0.00 per unit, and his total holdings …

MoneyHero Ltd (MNY) awards 20,065 RSUs to interim CEO and CFO Leung

MoneyHero Ltd (MNY) has granted 20,065 restricted share units (RSUs) to its interim CEO and CFO, Leung Ka Yip Danny, on June 25, 2026, at no cost. These RSUs represent a contingent right to receive Class A ordinary shares, with one-third vesting on June …

MoneyHero Ltd (MNY) grants director 42,556 RSUs vesting in 2026

MoneyHero Ltd. (MNY) director Daniel Hua-chang Wang was granted 42,556 restricted share units (RSUs), which are set to vest 100% on August 17, 2026, provided he remains with the company. The grant price for these RSUs was $0.00 per unit, and his total holdings …

Heron Therapeutics Inc (HRTX) News, Articles, Events & Latest Updates

This article provides recent news and updates for Heron Therapeutics Inc (HRTX), including its Q2 2026 earnings report where it missed revenue estimates and its Q1 2026 report showing a loss and lagging revenue. The company's stock was also added to Zacks' "Strong Sell" …

MoneyHero Ltd (MNY) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for MoneyHero Ltd (MNY), detailing its current earnings forecast score, analyst ratings, and price targets. It highlights that the company ranks 105 out of 485 in the Software & IT Services industry with an average price target of …

Hero MotoCorp up 3% after Q1 profit jumps 29%; brokerages split on stock with 'Buy', 'Sell' calls

India's Hero MotoCorp gains after quarterly profit rise

Director equity grant at MoneyHero Ltd (MNY) vests in 2026

MoneyHero Ltd (MNY) director Steven Teichman was granted 42,556 restricted share units (RSUs) on July 31, 2026, which are set to vest 100% on August 17, 2026, contingent upon his continued service. This transaction, reported late due to administrative oversight, increases his direct holdings …

Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Average Recommendation of "Hold" from Analysts

Heron Therapeutics (NASDAQ:HRTX) has received an average "Hold" recommendation from analysts, with a 12-month average price target of $2.50. The company recently reported a quarterly loss of $0.04 per share and revenue of $34.71 million, both below analyst expectations. Institutional investors and hedge funds …

Heron Therapeutics (NASDAQ:HRTX) Upgraded to Hold at Zacks Research

Zacks Research has upgraded Heron Therapeutics (NASDAQ:HRTX) from a "strong sell" to a "hold" rating, aligning with the broader analyst consensus. The biotechnology company, with a market capitalization of $96.8 million, recently missed its quarterly earnings and revenue estimates. Despite this, institutional investors hold …

Uber forecasts weak quarterly profit, doubles down on robotaxi investment plans

Aug 5 (Reuters) - Uber Technologies forecast current-quarter adjusted earnings below Wall Street estimates on Wednesday, saying that foreign exchange would trim bookings ‌growth and reaffirming plans to invest heavily in robotaxis and acquisitions. The global ‌ride-hailing and delivery giant's capital allocation has become …

Heron Therapeutics (HRTX) Projected to Post Quarterly Earnings on Monday

Heron Therapeutics (HRTX) is expected to report its Q2 2026 earnings before market open on Monday, August 10th, with analysts projecting a loss of $0.02 per share and revenue of $42.19 million. The company missed expectations in the previous quarter, reporting a $0.04-per-share loss …

Q1 Results This Week: SBI, Airtel, LIC, Titan, Hero MotoCorp, ONGC And 550+ Companies To Report Earnings

Heron Therapeutics, Inc. Revenue Breakdown – NASDAQ:HRTX

Heron Therapeutics, Inc. (NASDAQ:HRTX) generated $154.90 million USD in revenue last year, primarily from its Therapeutic Innovations segment. This represents an increase from $144.28 million USD in the previous year. All reported revenue for the company originated from the United States.

Heron Therapeutics Inc (HRTX) Institutional Confidence

Heron Therapeutics Inc (HRTX) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The company's institutional shareholding proportion is 90.02%, showing a quarter-over-quarter increase of 5.58%. James Simons is the largest institutional shareholder, holding 0.91% of …